As in past years, FiercePharma has tracked yearly data to compile the top CEO pay packages in biopharma, ranging from nearly $60M to $16M in 2018, and they’ve pointed out some notable trends. First, no women made the list. Big Pharma’s only female CEO, GlaxoSmithKline’s Emma Walmsley, fell short with a pay package of $7.75M.
However, some of her Big Pharma peers also fell short. Last year, Novartis’ Vas Narasimhan pulled in $9.9M, Roche’s Severin Schwan pulled in about $11.77M, and Sanofi’s Olivier Brandicourt took a pay cut to $8.2M. But perhaps the biggest change in 2018 is the emergence of biotech CEOs scattered throughout the list. The last trend noted is that company size didn’t exactly correlate with a bigger payday. The top 20 highest-paid biopharma CEOs of 2018 are listed below: